Unknown

Dataset Information

0

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects.


ABSTRACT: Aim:Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. The combination of a DPP-4 inhibitor with pioglitazone is a promising therapeutic option. The aim of the present study was to evaluate the pharmacokinetic and pharmacodynamic interaction between evogliptin and pioglitazone. Materials and Methods:A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence crossover study was conducted in healthy Korean male subjects. All subjects received evogliptin 5 mg once daily for 7 days (EVO), pioglitazone 30 mg once daily for 7 days (PIO) and co-administration of evogliptin 5 mg and pioglitazone 30 mg once daily for 7 days (EVO+PIO) according to the assigned sequence and period. Serial blood samples were collected for 24 hours for pharmacokinetic analysis and 3 hours after the oral glucose tolerance test for the pharmacodynamic analysis. Results:Thirty-four subjects completed the study. EVO+PIO and EVO showed a similar maximum plasma concentration at steady state (Cmax,ss) and area under the concentration-time curve during the dosing interval at the steady state (AUC?,ss) of evogliptin, with geometric mean ratios (GMRs) (90% confidence interval (CI)) of 1.01 (0.97-1.05) and 1.01 (0.98-1.04), respectively. EVO+PIO and PIO showed a similar Cmax,ss and AUC?,ss of pioglitazone, with GMRs (90% CI) of 1.07 (0.99-1.17) and 1.08 (0.99-1.17), respectively. Reduction of the glucose level after EVO+PIO was larger compared to PIO and similar with EVO. Conclusion:Concomitant administration of evogliptin and pioglitazone showed similar glucose-lowering effects with those of evogliptin alone without pharmacokinetic interactions when compared to the intake of each drug alone.

SUBMITTER: Hwang I 

PROVIDER: S-EPMC7591087 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects.

Hwang Inyoung I   Kim Yun Y   Yoo Hyounggyoon H   Jang In-Jin IJ   Yu Kyung-Sang KS   Lee SeungHwan S  

Drug design, development and therapy 20201023


<h4>Aim</h4>Evogliptin is a newly developed oral glucose-lowering medication of the dipeptidyl peptidase 4 (DPP-4) inhibitor class for type 2 diabetes mellitus. The combination of a DPP-4 inhibitor with pioglitazone is a promising therapeutic option. The aim of the present study was to evaluate the pharmacokinetic and pharmacodynamic interaction between evogliptin and pioglitazone.<h4>Materials and methods</h4>A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence c  ...[more]

Similar Datasets

| S-EPMC7699451 | biostudies-literature
| S-EPMC5723108 | biostudies-literature
| S-EPMC5915615 | biostudies-literature
| S-EPMC5298089 | biostudies-literature
| S-EPMC6099239 | biostudies-literature
| S-EPMC6063220 | biostudies-literature
| S-EPMC4348051 | biostudies-literature
| S-EPMC2686068 | biostudies-literature
| S-EPMC6548978 | biostudies-literature
| S-EPMC8617249 | biostudies-literature